Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

Inclusion Criteria:

* Age more than 18 years old, no gender limit.
* According to the Diagnosis and Treatment of Primary Lung Cancer (2018 edition), non-small cell lung cancer (NSCLC) was diagnosed by histopathology.
* Tumor Node Metastasis (TNM) staging is II-III.
* According to the National Comprehensive Cancer Network (NCCN) guidelines, patients who had failed, refused, or were not suitable for standard treatment (surgery, chemoradiotherapy, targeted) after consultation.
* Eastern Cooperative Oncology Group (ECOG), Performance Status (PS) Score ≤ 2.
* Estimated survival time is more than 3 months.
* The patient has signed informed consent.

Exclusion Criteria:

* The patient has previously received interventional therapy \[iodine seed implantation, ablation, bronchial arterial chemoembolization (BACE) therapy\], or received immunotherapy during the first-line standard treatment.
* The patient is accompanied by other malignant tumors and had not been cured.
* White blood cell \< 3×10\*9/L, absolute value of neutrophils \< 1.5×10\*9/L, neutrophil/lymphocyte ratio ≥ 3, platelet count \< 50×10\*9/L, hemoglobin concentration \< 90 g/L.
* Liver and kidney dysfunction (creatinine \> 176.8 μmol/L; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2 times the upper limit of normal).
* Uncorrectable coagulopathy or active hemoptysis.
* Patient with active infections requires antibiotic treatment.
* Patient has uncontrollable hypertension, diabetes, and cardiovascular disease with obvious symptoms.
* Allergy to contrast agents.
* Women with pregnancy or lactation.